Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China

Advances in Therapy

Volumn 25, Issue 8, 2008, Pages 752-774

  Palmer, James L ^a   Gibbs, Meaghan ^a   Scheijbeler, Huib W K F H ^a   Kotchie, Robert W ^a   Nielsen, Steffen ^b   White, Jeremy ^c   Valentine, William J ^a  

^a IQVIA   (United States)

^b NOVO NORDISK A S   (Denmark)

^c Novo Nordisk FemCare AG   (Switzerland)

Author keywords

Aspart; Biphasic; China; Cost effectiveness; Insulin; Modelling; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN, ASP(B28)-; UNCLASSIFIED DRUG;

ARTICLE; CHINA; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS; HEALTH CARE COST; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR;

CHINA; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 58749111643     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0080-4     Document Type: Article

References (57)

1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130-2135. (Pubitemid 41242456)
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053. (Pubitemid 38579764)
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431. (Pubitemid 28405191)
4. International Diabetes Federation. Diabetes Atlas. 3rd edition. Brussels: International Diabetes Federation; 2007.
5. Popkin BM. Nutrition in transition: the changing global nutrition challenge. Asia Pac J Clin Nutr. 2001;10(suppl):S13-S18. (Pubitemid 33739437)
6. Zhao W, Chen J. Implications from and for food cultures for cardiovascular disease: diet, nutrition and cardiovascular diseases in China. Asia Pac J Clin Nutr. 2001;10:146-152. (Pubitemid 33739347)
7. The maladies of afuence. The Economist. 9 August 2007. Available at: www.economist.com/world/international/displaystory.cfm?story-id=9616897. Accessed 2007.
8. Jia WP, Pang C, Chen L, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50:286-292.
9. Dong Y, Gao W, Nan H, et al. Prevalence of type 2 diabetes in urban and rural Chinese populations in Qingdao, China. Diabet Med. 2005;22:1427-1433. (Pubitemid 41391322)
10. World Health Organization. Diabetes is a common condition and its frequency is dramatically rising all over the world. Available at: www.who.int/diabetes/commoncondition/en. Accessed 2008.
11. Chan JC, Ng MC, Critchley JA, et al. Diabetes mellitus-a special medical challenge from a Chinese perspective. Diabetes Res Clin Pract. 2001;54(suppl 1):S19-S27. (Pubitemid 32907243)
12. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care. 1998;21:296-309.
13. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45:S5-S12. (Pubitemid 34762208)
14. Chen XB, Tang L, Chen HY. Assessing the impact of complications on the costs of type 2 diabetes in urban China. Chin J Diabetes. 2003;11:238-241.
15. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P. R. C hina. Value Health. 2008;11(suppl 1):S23-S32. (Pubitemid 351490455)
16. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
17. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000;14:667-685.
18. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin. 2005;21:1617-1629. (Pubitemid 41505028)
19. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation; 2005.
20. Te DCCT Research Group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
21. Te UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
22. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972. (Pubitemid 44156663)
23. Smith SA, Murad MH. Review: long-acting insulin analogues do not improve glycaemic control but reduce nocturnal hypoglycaemia. Evid Based Med. 2008;13:79. (Pubitemid 351836801)
24. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151-1167. (Pubitemid 29459810)
25. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 1983;6:374-377. (Pubitemid 13078719)
26. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;(19):CD003287.
27. Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23:3209-3214.
28. Khutsoane D, Sharma SK, Almustafa M, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10:212-222. (Pubitemid 351247337)
29. Sharma SK, Al-Mustafa M, Oh SJ, et al. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin. 2008;24:645-652. (Pubitemid 351428975)
30. Gao Y, Guo XH, Vaz JA, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diabetes Obes Metab. 2008; May 20. In press.
31. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-Effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20:S5-S26. (Pubitemid 39349905)
32. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20:S27-S40. (Pubitemid 39349906)
33. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412. (Pubitemid 30609442)
34. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
35. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419. (Pubitemid 30609443)
36. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679. (Pubitemid 33135349)
37. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33:1776-1781. (Pubitemid 34761059)
38. UK Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
39. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272-281. (Pubitemid 30090804)
40. World Health Organization. Life tables for 191 countries. World mortality in 2005. Available at: www3.who.int/whosis/life-tables/life-tables.cfm.2007. Accessed 2008.
41. World Health Organization. Global burden of disease estimates. 2004. Available at: www.who.int/healthinfo/bodestimates/en/index.html. Accessed 2008.
42. Annemans L, Demarteau N, Hu S, et al. An Asian regional analysis of cost-Effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy. Value Health. 2008;3:354-364. (Pubitemid 351712966)
43. Lin S. Nephrology in China: a great mission and momentous challenge. Kidney Int Suppl. 2003;(83):S108-S110. (Pubitemid 36126854)
44. Tomas GN, Critchley JA, Tomlinson B, et al. Peripheral vascular disease in type 2 diabetic Chinese patients: associations with metabolic indices, concomitant vascular disease and genetic factors. Diabet Med. 2003;20:988-995. (Pubitemid 41701479)
45. Xu L, Xie X, Wang S, et al. Prevalence of diabetes mellitus in China. Exp Clin Endocrinol Diabetes. 2008;116:69-70. (Pubitemid 351270912)
46. Valentine WJ, Palmer AJ, Nicklasson L, et al. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract. 2006;60:1138-1145. (Pubitemid 44226756)
47. Hsiao WC. The Chinese health care system: lessons for other nations. Soc Sci Med. 1995;41:1047-1055. (Pubitemid 26465953)
48. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523-1534. (Pubitemid 44297431)
49. International Society for Pharmacoeconomics and Outcomes Research. Chinese Medical Doctor Association Pharmacoeconomics Chapter. Pharmacoeconomic Guidelines. ISPOR 2005. Available at: www.pecn.org/en/pe-guidelines/index.asp. Accessed 2008.
50. World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization; 2003.
51. Barzi F, Patel A, Gu D, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007;61:115-121. (Pubitemid 46174217)
52. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-Effectiveness analysis up by its bootstraps: a non-parametric approach to confdence interval estimation. Health Econ. 1997;6:327-340. (Pubitemid 27384638)
53. World Health Organization. Report on Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization; 2001.
54. Central Intelligence Agency. The 2008 World Factbook. Washington: Central Intelligence Agency; 2008.
55. Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008;11(suppl 1):S11-S22. (Pubitemid 351490454)
56. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753-2758. (Pubitemid 33115423)
57. Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-Effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Tailand. Value Health. 2008;11(suppl 1):S43-S51. (Pubitemid 351490458)